Fundraising FoxHapten Sciences
Memphis, US · Founded 2011 · Delaware corporation · 1 known investors
Find your way into Hapten Sciences
Sign up to see every warm intro you have to Hapten Sciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Hapten Sciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Hapten Sciences develops early-stage pharmaceutical products focused on dermatological health, with its lead candidate PDC-APB in clinical development as a preventive immunotherapy for contact dermatitis caused by exposure to poisonous plants. The company targets healthcare providers and individuals affected by urushiol-related skin conditions.
Founders & leadership
RJ
Raymond J HageExecutive
Board
GP
Gary ProstermanBoard director
GS
SI
Stephen I. BandakBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$5.8M disclosed across 6 of 8 rounds · 2013–2021
▶$3MofferedAug 2021 · PharmaceuticalsRule 506(b)
▶$3MofferedAug 2021 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen L. BandakDirector
- Gary StevensonDirector
- Gary ProstermanExecutive Officer, Director
- Raymond J. HageExecutive Officer, Director
- Offering amount
- $3M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$886KraisedOct 2019 · 4 investors · PharmaceuticalsRule 506(b)
▶$886KraisedOct 2019 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Raymond J. HageExecutive Officer, Director
- Gary ProstermanExecutive Officer, Director
- Gary StevensonDirector
- Stephen L. BandakDirector
- Offering amount
- $1.5M
- Amount sold
- $886K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedSep 2018 · 5 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedSep 2018 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Raymond J. HageExecutive Officer, Director
- Stephen L. BandakDirector
- Gary StevensonDirector
- Gary ProstermanExecutive Officer, Director
- Offering amount
- $2.2M
- Amount sold
- $1.6M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedFeb 2017 · 8 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedFeb 2017 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Raymond J. HageExecutive Officer, Director
- Joseph ZakrzewskiDirector
- Gary StevensonDirector
- Stephen L. BandakDirector
- Gary ProstermanExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedJan 2016 · 6 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedJan 2016 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary StevensonDirector
- Joseph ZakrzewskiDirector
- Stephen I. BandakDirector
- Raymond J. HageExecutive Officer, Director, Promoter
- Gary ProstermanExecutive Officer, Director, Promoter
- Offering amount
- $1.7M
- Amount sold
- $1.2M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedApr 2015 · 7 investors · PharmaceuticalsRule 506(b)
▶$250KraisedApr 2015 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen I. BandakDirector
- Gary ProstermanExecutive Officer, Director, Promoter
- Raymond J HageExecutive Officer, Director, Promoter
- Gary StevensonDirector
- Offering amount
- $250K
- Amount sold
- $250K
- Minimum investment
- $3.1K
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$100KofferedFeb 2015 · PharmaceuticalsRule 506(b)
▶$100KofferedFeb 2015 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary ProstermanExecutive Officer, Director, Promoter
- Stephen I. BandakDirector
- Raymond J HageExecutive Officer, Director, Promoter
- Gary StevensonDirector
- Offering amount
- $100K
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$625KraisedFeb 2015 · 7 investors · PharmaceuticalsRule 506(b)
▶$625KraisedFeb 2015 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary ProstermanExecutive Officer, Director, Promoter
- Raymond J HageExecutive Officer, Director, Promoter
- Stephen I. BandakDirector
- Gary StevensonDirector
- Offering amount
- $1.2M
- Amount sold
- $625K
- Minimum investment
- $25K
- Placement agents
- NA
- First sale
- May 2013
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Read on Scientific AmericanScientific American is a media organization that publishes research and ideas across science, health, technology and society through multiple formats including print, web, video, and podcasts. Founded in 1845, it reaches over 20 million people monthly and maintains editorial independence while providing trustworthy science communication and commentary.
EpiphanydermatologyEpiphany Dermatology operates dermatology clinics staffed by board-certified dermatologists, physician assistants, nurse practitioners, and aestheticians, offering medical services such as skin cancer care, Mohs surgery, biopsies, and acne treatment, as well as cosmetic services like chemical peels, injectable fillers, and body contouring. It also sells physician-approved skin care products and aims to provide accessible dermatologic care across multiple U.S. locations.
Companies working in the same space as Hapten Sciences.
Frequently asked questions
- What does Hapten Sciences do?
- Hapten Sciences develops early-stage pharmaceutical products focused on dermatological health, with its lead candidate PDC-APB in clinical development as a preventive immunotherapy for contact dermatitis caused by exposure to poisonous plants. The company targets healthcare providers and individuals affected by urushiol-related skin conditions.
- Who are Hapten Sciences's investors?
- Hapten Sciences's investors include MB Venture Partners.
- How much funding has Hapten Sciences raised?
- Hapten Sciences has disclosed $5.8M raised across 6 of its 8 known rounds.
- Where is Hapten Sciences headquartered?
- Hapten Sciences is headquartered in Memphis, US.